Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus

Gene

Volumn 529, Issue 2, 2013, Pages 340-344

  Zhang, Ling Yun ^a   Jin, Yong Jun ^a   Jin, Qing Song ^a   Lin, Liang Yan ^a   Zhang, Dong Dong ^a   Kong, Li Li ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Adipocytokine; Insulin resistance; Non alcoholic fatty liver disease; Single nucleotide polymorphism

Indexed keywords

RESISTIN;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

Γ-GT; ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; ALT; ASPARTATE TRANSAMINASE; AST; BMI; BODY MASS INDEX; C/EBP; CCAAT/ENHANCER BINDING PROTEIN; FASTING BLOOD GLUCOSE; FASTING INSULIN; FBG; FINS; GAMMA-GLUTAMYL TRANSFERASE; HDL; HEMATOPOIETIC STEM CELLS; HIGH DENSITY LIPOPROTEIN; HSCS; INSULIN RECEPTOR SUBSTRATE; INSULIN RESISTANCE; IRS; LDL; LOW DENSITY LIPOPROTEIN; MAPK; MITOGEN-ACTIVATED PROTEIN KINASE; NAFLD; NASH; NON-ALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PHOSPHATIDYL INOSITOL 3-KINASE; PI-3K; PPAR; RESISTIN; RETN; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISMS; SNPS; SOCS; SUPPRESSOR OF CYTOKINE SIGNALING; T2DM; TC; TG; TNF; TOTAL CHOLESTEROL; TRIGLYCERIDE; TUMOR NECROSIS FACTOR; TYPE 2 DIABETES MELLITUS; WAIST-TO-HIP RATIO; WHR;

ADULT; CASE-CONTROL STUDIES; CHINA; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RESISTIN;

EID: 84883791970     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.08.001     Document Type: Article

References (30)

1. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2007, 25(8):883-889.
2. Bertolani C., et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am. J. Pathol. 2006, 169(6):2042-2053.
3. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Taekowski A. Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 2005, 174(9):5789-5795.
4. Chinese Association for the Study of Liver Disease Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. Chin. J. Hepatol. 2010, 18(3):163-166.
5. Chitturi S., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35(2):373-379.
6. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114(4):842-845.
7. de Alwis N.M., Day C.P. Nonalcoholic fatty liver disease: the mist gradually clears. J. Hepatol. 2008, 48(Suppl. 1):S104-S112.
8. Ding B.J., Wang Z., Yang Y., Liu C., Piao Y.F. Association between single nucleotide polymorphisms at the -2548 site in leptin gene and nonalcoholic fatty liver disease in patients with type 2 diabetes. World Chin. J. Digestol. 2009, 17(26):2732-2737.
9. Fan J.G., Farrell G.C. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol. 2009, 50(1):204-210.
10. Fan J.G., et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?. J. Gastroenterol. Hepatol. 2007, 22(6):794-800.
11. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl. 1):S99-S112.
12. Gambino R., Cassader M., Pagano G., Furazzo M., Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?. Hepatology 2007, 45(5):1097-1107.
13. McCullough A.J. Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2006, 40(Suppl. 1):S17-S29.
14. Merriman R.B., Aouizerat B.E., Bass N.M. Genetic influences in nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 2006, 40(Suppl. 1):S30-S33.
15. Muse E.D., et al. Role of resistin in diet-induced hepatic insulin resistance. J. Clin. Invest. 2004, 114(2):232-239.
16. Ruhl C.E., Everhart J.E. Epidemiology of nonalcoholic fatty liver. Clin. Liver Dis. 2004, 8(3):501-519.
17. Silswal N., Singh A.K., Aruna B., Mukhopadhyay S., Ghosh S., Ehtesham N.Z. Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem. Biophys. Res. Commun. 2005, 334(4):1092-1101.
18. Song H., et al. Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. Biochem. Biophys. Res. Commun. 2002, 299(2):291-298.
19. Steppan C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-312.
20. Tan M.S., Chang S.Y., Chang D.M., Tsai J.C., Lee Y.J. Association of resistin gene 3'-untranslated region +62G->A polymorphism with type 2 diabetes and hypertension in a Chinese population. J. Clin. Endocrinol. Metab. 2003, 88(3):1258-1263.
21. Tokushige K., Takakura M., Tsuchiya-Matsushita N., Taniai M., Hashimoto E., Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 2007, 46(6):1104-1110.
22. Tokushige K., et al. Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. J. Gastroenterol. 2009, 44(9):976-982.
23. Tomaru T., Steger D.J., Lefterova M.I., Schupp M., Lazar M.A. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteins. J. Biol. Chem. 2009, 284(10):6116-6125.
24. Tsukahara T., et al. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res. Clin. Pract. 2009, 84(2):179-186.
25. Valenti L., et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002, 122(2):274-280.
26. Vernochet C., et al. C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol. Cell. Biol. 2009, 29(17):4714-4728.
27. Wiegand J., Mossner J., Tillmann H.L. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Der Internist 2007, 48(2):154-163.
28. World Health Organization Definition, diagnosis and classifications of diabetes mellitus and its complications. Report of a WHO consultation, Part 1: Diagnosis and classification of diabetes mellitus 1999, WHO, Geneva.
29. Zhou B. Cooperative meta-analysis group of China obesity task force. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. Chin. J. Epidemiol. 2002, 23(1):5-10.
30. Zhou L., Li Y., Xia T., Feng S., Chen X., Yang Z. Resistin overexpression impaired glucose tolerance in hepatocytes. Eur. Cytokine Netw. 2006, 17(3):189-195.